HT-6184 is under clinical development by Halia Therapeutics and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HT-6184’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HT-6184 overview

HT-6184 is under development for the treatment of thermal hyperalgesia and mechanical allodynia, Alzheimer’s disease, myelodysplastic syndrome (MDS), chronic inflammation, acute myeloid leukemia (AML), post-procedure acute Inflammation and pain and unspecified ophthalmological disorder. It acts by targeting NEK7/NLRP3. It is administered through oral route.

It was under development for neuroinflammation.

Halia Therapeutics overview

Halia Therapeutics (Halia) is a preclinical-stage biopharmaceutical company. It is headquartered in Lehi, Utah, the US.

For a complete picture of HT-6184’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.